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Abstract
Background: Bone morphogenetic protein 4 (BMP4) plays an important role in cancer pathogenesis. In breast
cancer, it reduces proliferation and increases migration in a cell line-dependent manner. To characterize the
transcriptional mediators of these phenotypes, we performed RNA-seq and DNase-seq analyses after BMP4
treatment in MDA-MB-231 and T-47D breast cancer cells that respond to BMP4 with enhanced migration and
decreased cell growth, respectively.
Results: The RNA-seq data revealed gene expression changes that were consistent with the in vitro phenotypes
of the cell lines, particularly in MDA-MB-231, where migration-related processes were enriched. These results were
confirmed when enrichment of BMP4-induced open chromatin regions was analyzed. Interestingly, the chromatin
in transcription start sites of differentially expressed genes was already open in unstimulated cells, thus enabling
rapid recruitment of transcription factors to the promoters as a response to stimulation. Further analysis and
functional validation identified MBD2, CBFB, and HIF1A as downstream regulators of BMP4 signaling. Silencing
of these transcription factors revealed that MBD2 was a consistent activator of target genes in both cell lines, CBFB
an activator in cells with reduced proliferation phenotype, and HIF1A a repressor in cells with induced migration
phenotype.
Conclusions: Integrating RNA-seq and DNase-seq data showed that the phenotypic responses to BMP4 in breast
cancer cell lines are reflected in transcriptomic and chromatin levels. We identified and experimentally validated
downstream regulators of BMP4 signaling that relate to the different in vitro phenotypes and thus demonstrate
that the downstream BMP4 response is regulated in a cell type-specific manner.
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Background
Despite many advances in diagnostics and therapeutics,
breast cancer remains the leading cause of cancer death
in women [1]. Bone morphogenetic proteins (BMPs) are
a group of growth factors that are important players
during development [2, 3] but also contribute to cancer
formation and progression [4–6]. As a subfamily of the
transforming growth factor β (TGF-β) protein superfam-
ily, BMPs are extracellular ligands that bind as dimers to
their specific transmembrane receptors and activate the
intracellular SMAD signaling pathway leading to phos-
phorylation of receptor-regulated SMADs (SMAD1/5/9).
The activated SMADs bind to SMAD4 and the complex
translocates to the nucleus where it regulates the expres-
sion of BMP target genes [7, 8]. Alternatively, BMP signals
are also mediated through the activation of ERK, JNK and
p38 mitogen-activated protein kinase pathways [7, 8].
The functional consequences of BMP signaling depend
on the BMP ligand and tissue type. We and others have
shown that BMP4 reduces the proliferation of breast can-
cer cell lines, while simultaneously inducing migration
and invasion in a subset of cell lines [9–11]. Similar
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dualistic effects upon BMP4 stimulation have also been
reported in other tumor types [12]. Concordantly, data
from breast cancer patient samples point to a correlation
between elevated BMP4 levels and reduced proliferation
as well as an increased risk of recurrence [13]. These
BMP4-related effects that seem either detrimental
(reduced cell growth) or beneficial (increased mobility)
for the cancer cells are likely to be mediated by specific
BMP4 target genes. The identification of such target
genes is thus important since it may allow generation
of effective cancer therapies targeting each phenotype
independently.
We have previously searched for BMP4 target genes in
a set of breast cancer cell lines that predominantly re-
spond to BMP4 treatment by reduction of proliferation
[14]. Here, we used next-generation sequencing (NGS)
technologies (RNA-seq and DNase-seq) to uncover
BMP4-mediated transcriptional events with a specific
focus on comparing cells in which BMP4 has opposing ef-
fects, namely antiproliferative and promigratory. Out of
the nine breast cancer cell lines we have previously stud-
ied, T-47D shows one of the most prominent growth
reductions and MDA-MB-231 cells display the most overt
induction of migration [9, 10], and were thus selected for
this study.
RNA-seq method quantifies the level of gene expres-
sion across the genome [15] while DNase-seq allows
identification of open chromatin regions that are sensi-
tive to digestion by the DNase I endonuclease [16].
Open chromatin regions are considered as sites where
transcriptional regulation can take place since they are
accessible for regulatory molecules to bind and exert
their function. By combining data from RNA-seq and
DNase-seq, and using additional data analysis tools, it
was possible to identify candidate transcription factors
involved in the observed transcriptional responses. This
approach thus provides the means to better understand
the transcriptional events that link BMP4 signaling and
its resulting phenotypes.
Results
We performed RNA-seq and DNase-seq analyses in two
breast cancer cell lines, T-47D and MDA-MB-231. The
cell lines were treated with BMP4 and vehicle control
for 3 h, thus allowing us to specifically focus on early re-
sponse events. Both vehicle- and BMP4-treated cell lines
were sequenced (see methods).
BMP4-elicited transcriptional regulation is highly
divergent in the two breast cancer cell lines with different
functional responses to BMP4
Sequencing reads from RNA-seq and DNase-seq were
aligned to the human genome and further analyzed as de-
scribed in the methods. To confirm that the two datasets
were consistent, we compared the chromatin openness as
determined by DNase-seq signal at the transcription start
site (TSS) to the expression level of the gene as deter-
mined by RNA-seq. As expected, we found that the in-
creased openness of TSS globally correlated with
increased gene expression (Additional file 1: Figure S1,
Panels A and B). However, the variance is high, indicating
that the differences in the chromatin state only partly ex-
plain gene expression patterns.
Next we compared the expression levels from RNA-seq
between the vehicle- and BMP4-treated cells. This analysis
identified 91 differentially expressed genes (DEGs) in
MDA-MB-231, of which 58 were upregulated and 33
downregulated (Additional file 2: Table S1). In T-47D,
there were 203 DEGs, of which 160 were upregulated and
43 were downregulated (Additional file 3: Table S2). In
total, 10 DEGs (ATOH8, BDKRB2, BMF, GS1-124 K5.4,
ID1, ID2, ID3, SKIL, SMAD6, and SMAD9) were shared
by the two cell lines and all of them were upregulated ex-
cept GS1-124 K5.4 which was downregulated in both cell
lines. To illustrate that BMP4 induces markedly divergent
transcriptional responses in these two cell lines, we gener-
ated a heatmap to show the expression levels of the
protein-coding DEGs (Fig. 1a). Using the DNase-seq data,
we examined the chromatin status at the transcription
start sites (TSSs) of these protein-coding DEGs. For the
majority of the cases the chromatin was open at the TSS
before BMP4 stimulation (approximately 86% of all DEGs
in both cell lines) (Additional file 1: Figure S1, Panels C
and D). For the remaining DEGs, we observed either
opening or closing of the TSS after stimulation or no
change in the closed chromatin status (Fig. 1a). These data
indicate that, at this early time point, the BMP4-induced
differential expression mainly involves genes whose tran-
scription does not require changes in the chromatin status
at TSS.
The DEG lists included a number of genes involved
in the canonical BMP pathway. As expected, ID1, ID2
and ID3, known BMP4 target genes, were upregulated
in both cell lines (Fig. 1b). Similarly, the receptor-
regulated SMAD9 was upregulated in both cell lines
whereas no significant difference in the other receptor-
regulated SMADs or SMAD4 expression was observed.
Among the inhibitory SMADs, SMAD6 was upregu-
lated in both cell lines and SMAD7 in T-47D. In
addition, the BMP type I receptor BMPR1A and nega-
tive regulators of BMP signaling, NOG and BAMBI,
were upregulated in T-47D while in MDA-MB-231
their expression was not significantly changed (Fig. 1b).
Thus BMP4 stimulation leads to expression changes
having characteristics of both feedback and feedforward
loops.
We then evaluated whether the differentially expressed
genes participate in specific biological processes and
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Fig. 1 The RNA-seq and DNAse-seq data reveal cell line-specific responses to BMP4. a Gene expression levels of differentially expressed
protein-coding genes converted to log2 scale are shown for both cell lines and treatments, upregulated genes on the left and downregulated
genes on the right. The status column denotes the cell line in which the gene is differentially expressed. The rightmost columns indicate the
status of the chromatin at transcription start sites (TSS) of the DEGs as measured by DNAse-seq. b Illustration of the differentially expressed
components of the BMP signaling pathway upon BMP4 treatment
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especially assessed whether the non-common DEGs have
differing functions. To this end we used DAVID to
search for GO terms enriched in the sets of non-
common protein-coding DEGs. In MDA-MB-231, most
of the enriched terms were related to cell migration
whereas organ development and morphogenesis as well
as intracellular signaling were the most significant GO
terms in T-47D (Table 1). These findings imply that the
transcriptional changes are indeed likely to explain the
dissimilarities in the phenotypic responses of these two
cell lines to BMP4 treatment.
Thereafter, we also wanted to investigate whether the
expression levels of DEGs could be linked with survival
in breast cancer patients. For this purpose, we used the
data publicly available in the TCGA database. The re-
sults showed that 20 DEGs in the MDA-MB-231 and 46
DEGs in the T-47D cells associated with either good or
poor prognosis (Additional file 4: Tables S3 and S4). Of
the nine shared protein-coding DEGs, four (ATOH8,
ID3, SMAD6 and SMAD9) were correlated with survival,
all being associated with poor prognosis.
To validate the results of the RNA-seq analysis and to
extend the scope of the study beyond the 3 h time point
in two cell lines, qRT-PCR was used to study the
expression levels of 15 selected DEGs in MDA-MB-231
and T-47D cells as well as in five additional breast
cancer cell lines (BT-474, HCC-1954, MCF-7, MDA-
MB-361, and MDA-MB-436) and one normal breast
epithelial cell line (MCF-10A) treated with BMP4 and
vehicle for 3, 6 and 24 h. The genes were selected based
on their expression levels and reported cancer associ-
ation in the literature, and five of these were upregu-
lated according to the RNA-seq in both MDA-MB-231
and T-47D. The expression patterns of the majority of
the genes showed similarities across the cell line panel
and time points with the clear exception of MDA-MB-
436, in which the expression changes were very limited
(Fig. 2). Particularly the five shared genes (ATOH8, ID2,
SKIL, SMAD6 and SMAD9) as well as DLX3 were con-
sistently upregulated upon BMP4 treatment throughout
the time series thus confirming that they represent
common BMP4 target genes. The remaining genes
showed more variability with altered expression typic-
ally in only two to three cell lines, suggesting that their
expression is likely to be influenced by factors that are
cell line-specific.
Chromatin landscape and dynamics following BMP4
treatment
To gain more insight into the changes of chromatin struc-
ture during BMP4 treatment, we performed peak detec-
tion in a genome-wide manner to identify the areas of
open chromatin. The peak detection approach was bench-
marked by comparison to publicly available DNase-seq
data of unstimulated T-47D cell line from ENCODE (see
methods), showing that most of the peaks identified in
our data are present also in ENCODE samples (Additional
file 5: Table S5).
After filtering procedures (see methods), the numbers
of identified DNase hypersensitive sites (DHSs) in the
MDA-MB-231 cell line were 89,830 and 97,349 in ve-
hicle- and BMP4-treated samples, respectively. In T-
47D, the corresponding numbers were 68,000 and
73,881. To obtain a unified set of peaks for both condi-
tions, the overlapping DHSs were merged resulting in a
total of 106,154 DHSs in MDA-MB-231 and 110,028 in
T-47D. After the merging, the fraction of shared DHSs
between BMP4 and vehicle control in MDA-MB-231 sam-
ples was 75% while the fraction of unique DHSs in the ve-
hicle was 9% and correspondingly in the BMP4 sample
16% (Additional file 6: Figure S2). In the T-47D cell line,
Table 1 Gene ontology analysis
Cell line GO accession GO term Number of genes Adjusted p-value
MDA-MB-231 GO:0030334 regulation of cell migration 5 2.0 × 10−2
GO:0030335 positive regulation of cell migration 4 2.3 × 10−2
GO:2000145 regulation of cell motility 5 2.4 × 10−2
GO:2000147 positive regulation of cell motility 4 2.5 × 10−2
GO:0051272 positive regulation of cellular component movement 4 2.7 × 10−2
T-47D GO:0048513 animal organ development 45 2.6 × 10−8
GO:0035556 intracellular signal transduction 41 4.5 × 10−8
GO:0009887 organ morphogenesis 22 4.0 × 10−7
GO:0009966 regulation of signal transduction 36 4.5 × 10−6
GO:0007166 cell surface receptor signaling pathway 34 9.5 × 10−5
The DAVID Functional Annotation Tools was used to reveal significantly enriched GO categories among the differentially expressed protein-coding genes. The analysis
was done independently for each cell line and shared differentially expressed genes were omitted. The top five biological function GO terms are shown
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the fraction of shared DHSs between the two condi-
tions was 27% whereas the fraction of unique DHSs in
the vehicle was 34% and in the BMP4 sample 39%
(Additional file 6: Figure S2).
Annotation of the merged DHSs to genomic features
revealed a similar distribution in the two cell lines in the
vehicle-treated condition, with the largest fraction (>30%)
of DHSs locating in introns (Fig. 3a). When comparing
the distributions of the BMP4-induced DHSs between the
cell lines apparent resemblances were also observed. In
both cell lines, the proportion of DHSs associated with
intronic and intergenic regions increased after BMP4
stimulation with a corresponding decrease at other gen-
omic locations, including the promoter regions (Fig. 3b).
Fig. 2 Expression levels of selected BMP4 target genes by qRT-PCR in a breast cancer cell line panel. The expression levels of 15 DEGs were measured
after 3, 6 and 24 h of BMP4 treatment in the indicated cell lines. The color code illustrates the relative expression levels in the BMP4-treated sample as
compared to the corresponding vehicle control. FC = Fold change, n.a. = mRNA level too low to allow reliable measurement
A
B
Fig. 3 Distribution of open chromatin regions. Annotation of open chromatin regions in MDA-MB-231 and T-47D after (a) vehicle treatment (basal
openness) and (b) BMP4 treatment (consisting only of the chromatin that opened after BMP4 treatment)
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To assess the functional impact of the BMP4-induced
global changes in the chromatin structure we conducted
an enrichment analysis using GREAT [17] which maps
the DHSs to putative regulatory regions of genes and
conducts a gene ontology enrichment analysis. The re-
sults highlighted e.g. cell motility and organ morphogen-
esis as enriched biological functions for MDA-MB-231
and T-47D, respectively (Additional file 7: Tables S6 and
S7). These results are consistent with those obtained by
enrichment analysis of the differentially expressed genes
from RNA-seq (Table 1) and thereby suggest that, to-
gether with specific target genes, BMP4-induced changes
at chromatin level may contribute to the emergence of
the different BMP4-mediated phenotypes.
Transcription factor binding site enrichment analysis in
open chromatin regions of promoters reveals
transcription factors involved in BMP4 signaling
regulation
Based on our TSS openness analysis (Fig. 1a), a domin-
ant feature of our data is that the chromatin of the puta-
tive BMP4 target genes (identified by RNA-seq) is open
already in vehicle-treated cells. This is further supported
by our genome-wide peak analysis, where the promoter
regions were not overrepresented after the treatment
(Fig. 3b). Therefore, the alterations in the chromatin
state only partially explain gene expression differences
induced by the BMP4 treatment. However, differential
transcription factor binding to open promoters may ex-
plain the different responses in the cell lines. Therefore
we performed transcription factor (TF) motif binding
analysis. To assess which TFs might be regulators of the
BMP4 response, the sequences of open chromatin sites in
the proximal promoters of upregulated genes were ana-
lyzed with a total of 426 position weight matrixes (PWMs),
representing 401 individual TFs or TF-complexes (see
methods). For each TF we calculated an enrichment score
(see methods) for the number of binding sites in either
MDA-MB-231 or T-47D cells.
This analysis led to the identification of candidate
regulator TFs, including multiple members of the SMAD
family of TFs, as expected, as well as a number of shared
common regulator TFs. To focus on biologically relevant
candidates, we filtered out those TFs that were not
expressed based on our RNA-seq data. In addition, we
included only those TFs whose binding sites (TFBSs) in
open chromatin regions of the promoters of DEGs were
enriched in one and depleted in the other cell line. The
top 15 TFs that are expressed in both cell lines but have
a high enrichment score only in one of the cell lines are
listed in Tables 2 and 3. Examples of target gene pro-
moters with binding motifs for predicted TFs are shown
in Fig. 4a.
For more in-depth functional analysis we selected
particular TFs from the top enriched candidates using
the following criteria: 1) a binding motif with a quality
category of A-C in the HOCOMOCO database, 2) rele-
vance in the context of our model based on literature,
3) not a highly common regulator or part of a large TF
family, and 4) high expression level of the TF (>1000
reads) in at least one cell line and differential expres-
sion between cell lines according to the RNA-seq. The
Table 2 Top 15 transcription factors enriched in MDA-MB-231 cells
TF name Motif Selection by: TF binding sites Ref. sites Expected sites in ref. Ratio of enrichment Mean read count
MYBL2 MYBB_f1 2, 3, 4 12 2930 6.2 1.92 2197
BACH1 BACH1_si 1, 2, 3 15 3904 8.3 1.81 531
MYC MYC_f1 1, 2, 4 10 2698 5.7 1.74 3044
MAFK MAFK_si 2, 3 16 4428 9.4 1.70 688
RELA TF65_f2 1, 2, 4 19 5467 11.6 1.63 1398
PPARA PPARA_f1 1, 2, 3 9 2747 5.8 1.54 185
NFIA/B/C/X a 1, 2, 3 15 4669 9.9 1.51 b
NFIL3 NFIL3_si 1, 2, 3 11 3494 7.4 1.48 474
FOXA2 FOXA2_f1 1, 2, 3 36 11477 24.4 1.47 434
REL REL_do 1, 2, 3 17 5422 11.5 1.47 69
ZFHX3 ZFHX3_f1 2, 3 46 14683 31.2 1.47 66
RXRB RXRB_f1 1, 2, 4 20 6414 13.6 1.47 1015
SMARCC1 SMRC1_f1 1, 4 20 6443 13.7 1.46 1478
ETV5 ETV5_f1 2, 3 16 5199 11.1 1.45 641
NR3C1 GCR_si 1, 2, 4 15 4910 10.4 1.44 1087
The ratio of enrichment is the result of dividing the number of TF binding sites by the number of expected sites. Motifs are derived from the HOCOMOCO
database. aNFIA + NFIB + NFIC + NFIX_f2, bRead count range (51, 148, 748, 444, respectively). Ref. reference
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last criteria was used to ensure methodological success
in subsequent functional assays. With the criteria de-
scribed above CBFB, HIF1A, and MBD2 were selected
for further study. Of these, MBD2 had a large number
of binding sites in the promoters of our DEGs while
binding sites of the other two TFs were less widespread.
In addition, SMAD4 was used as a positive control.
As SMAD4 is a known regulator of BMP signaling,
we performed co-occurrence analysis of the binding
sites between our three candidate TFs and the SMAD
motifs. We found that the MBD2 motif was signifi-
cantly co-localized with the GC-rich SMAD4 consensus
motifs CGCC (P = 1.1e-9), GCCGnCGC (P = 1.3e-14),
and GGCGCC (P = 2e-10). As binding sites for CBFB or
HIF1A were less frequent across DEGs, statistical signifi-
cance for co-localization with SMAD motifs could not be
reliably evaluated. However, we did find several promoters
where SMAD binding sites co-localized with these factors.
Silencing of selected TFs (SMAD4, CBFB, HIF1A, and
MBD2) was then used to further evaluate their impact
on BMP4 signaling. After 48 h of silencing, the cells
were treated with BMP4 for 24 h and the mRNA levels
of the validated DEGs were measured to assess whether
the silencing influences BMP4 target gene expression
(Fig. 4b and Additional file 8: Figure S3). Downregula-
tion of SMAD4 was able to reverse the BMP4-mediated
change in the expression of all the tested target genes in
both MDA-MB-231 and T-47D cells (Fig. 4c) indicating
that these expression changes are indeed transmitted via
the canonical BMP pathway. For most of the target
genes, MBD2 silencing led to abrogation of the BMP4-
mediated induction in gene expression in both cell lines.
In T-47D cells, similar data was also obtained for most
of the genes upon CBFB (9/10) and HIF1A depletion
(6/10). However in MDA-MB-231, silencing of HIF1A
resulted exclusively in upregulation of the target genes
and both enhanced and diminished expression was seen
after CBFB downregulation. Of note, silencing of all of
the TFs in T-47D cells led to the enhanced expression
of the DLL1 gene, which was consistent with it being
downregulated upon BMP4 treatment. These data imply
that the TFs may function as either repressors or enhancers
of BMP4 target gene expression in a context-dependent
manner.
Discussion
We have previously characterized transcriptional responses
of breast cancer cell lines to BMP4 by using microarray
technology [14]. However, in that study we focused only
on cells that respond to BMP4 by reduced proliferation.
Efforts by others to examine BMP signaling target genes
have concentrated exclusively on non-cancerous cells
[18–20]. Here we set out to uncover the transcriptional
responses of breast cancer cell lines with different phe-
notypes by using one cell line that responds to BMP4
by reduced proliferation (T-47D) and another that re-
acts with increased migration (MDA-MB-231). Being
able to uncover the mechanisms of these two different
responses is essential for the understanding of the role
of BMP4 in breast cancer pathogenesis. To this end, we
used a substantially new approach of combining DNase-
seq, RNA-seq and functional experiments.
In order to find the early mediators of BMP4 response,
we treated the cells with BMP4 or vehicle control for
Table 3 Top 15 transcription factors enriched in T-47D cells
TF name Motif Selection by: TF binding sites Ref. sites Expected sites in ref. Ratio of enrichment Mean read count
MBD2 MBD2_si 1, 2, 3, 4 101 6664 39.6 2.55 571
TFAP2A AP2A_f2 1, 2, 3 115 10363 61.6 1.87 941
E4F1 E4F1_f1 2, 3 18 1750 10.4 1.73 310
SP1 SP1_f1 1, 2 392 41453 246.3 1.59 838
CUX1 CUX1_f1 1, 2, 3 13 1462 8.7 1.50 141
E2F2 E2F2_f1 1, 2 17 1941 11.5 1.47 215
AHR AHR_si 1, 2, 3 9 1030 6.1 1.47 791
SP2 SP2_si 1, 2 140 16512 98.1 1.43 672
CREB1 CREB1_f1 1, 2, 3 23 2720 16.2 1.42 177
CBFB PEBB_f1 1, 2, 3, 4 46 5461 32.4 1.42 457
ZIC2 ZIC2_f1 1, 2, 3 46 5487 32.6 1.41 118
ZFX ZFX_f1 1, 2, 3 127 15650 93.0 1.37 287
HIF1A HIF1A_si 1, 2, 3, 4 15 1890 11.2 1.34 1847
E2F3 E2F3_si 1, 2, 3 16 2019 12.0 1.33 322
XBP1 XBP1_f1 1, 3, 4 12 1545 9.2 1.31 22744
The ratio of enrichment is the result of dividing the number of TF binding sites by the number of expected sites. Motifs are derived from the HOCOMOCO
database. Ref. reference
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3 h. At this time point, the canonical BMP pathway
through SMAD1/5/9 is already activated [9]. The results
of RNA-seq revealed that the cell lines responded to
BMP4 by upregulating or downregulating a set of genes
that were mostly cell line-specific, with only ten com-
mon DEGs identified. Consistent with the sequencing
data, validation with qRT-PCR across multiple time points
(3, 6, and 24 h) and five additional cell lines further con-
firmed in a wider context the existence of common BMP4
target genes as well as cell line-specific expression pat-
terns. Of the ten shared DEGs, three were known BMP4
target genes (ID1-3) and two members of the BMP
A
B C
Fig. 4 Examples of predicted TFBSs and the impact of transcription factors on BMP4 target gene expression. a The predicted binding sites of
transcription factors MBD2, HIF1A and CBFB are depicted at the promoters of NOG, SMAD7 and ID1 genes, respectively. In addition, known BMP-response
elements (BRE) located near the binding sites are illustrated. b The TFs were silenced and the cells were treated with BMP4 or vehicle control followed by
measurement of target gene expression by qRT-PCR. Examples of relative expression levels of SKIL after HIF1A silencing in MDA-MB-231 cells (top panel)
and NOG expression after MBD2 silencing in T-47D cells (bottom panel) are shown. c Graphical summary of the TF silencing experiments. The order of
the genes is identical to that in Fig. 2. Blue color (decreased target gene expression) denotes TFs that were essential for target gene expression and red
color those whose silencing led to enhanced target gene expression. Not applicable indicates cases where BMP4 did not alter the baseline
gene expression. Data on the DLL1 gene, which is downregulated in T-47D upon BMP4 treatment, are highlighted with a bold line
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signaling pathway (SMAD6, SMAD9) [3]. The activa-
tion of the inhibitory SMAD6 indicates a negative
feedback loop, which in T-47D is reinforced by the
upregulation of BMP antagonist NOG and the pseudor-
eceptor BAMBI. On the other hand, activation of the
receptor-regulated SMAD9 seems to point to a positive
feedback loop, as alongside other R-SMADs, SMAD9
has been found to enhance BMP signaling [21, 22].
However, one study indicated that SMAD9 may have
an inhibitory role in BMP signaling [23]. In any case,
upregulation of SMAD9 due to BMP4 treatment has
also been recently reported in various cell types, for
example in primary fibroblasts, hepatocellular carcin-
oma and melanoma cells [24].
To understand the function of the cell line-specific
DEGs, we used GO analysis to segregate the DEGs into
biological process categories and discovered that the re-
sults reflected the response of the cell lines to BMP4.
Processes related to migration were enriched in the
MDA-MB-231 cells, whereas more diverse responses
were found in T-47D, including categories comprised of
signaling, development and morphogenesis. These find-
ings were corroborated by the DNase-seq data, where
we found that BMP4-induced global open chromatin
sites were enriched with the same biological categories
that were found with RNA-seq data. While categories
associated with signaling were observed in both cell
lines, in MDA-MB-231 those related to migration were
enriched. These data extend our previous results show-
ing enrichment of differentially expressed genes in GO
categories that were associated with the BMP4-induced
decrease in proliferation [14]. Taken together, the differ-
ent responses of the cell lines to BMP4 are reflected
both at the transcriptional and chromatin levels.
In the analysis of TSS chromatin state we could
observe changes in only a few of the genes that were dif-
ferentially regulated by BMP4. This might be due to the
fact that the 3 h stimulation of BMP4 is too short for
most of the TSSs to change their chromatin status.
Moreover, we could observe that in many cases the
chromatin was already open at the TSS, in which case
further changes are not needed to enhance the transcrip-
tional activity. Together with the observation that there
is a large variation between the chromatin status and
gene expression when we extend the analysis to the
whole set of protein-coding genes, it can be concluded
that the chromatin state of TSSs explains the observed
expression patterns only to a small extent. This result
was not unexpected, as gene expression is also com-
monly regulated from regions located far from the TSS,
such as enhancers [25, 26].
With genome-wide detection of open chromatin areas
we noticed that BMP4 stimulation induces opening of the
chromatin mostly in the intronic and intergenic regions.
This is consistent with the fact that changes in the TSS
and promoter regions were observed with only a few of
the differentially expressed genes. Opening of the in-
tronic sequences may indicate increased level of RNA
polymerase activity at gene bodies. Chromatin opening
at intergenic regions might suggest that additional
regulatory control is being attained in large extent
through distal regulatory elements such as enhancers
and silencers. Thus, already at the early 3-h time point
we are able to observe conformational changes that
cells may utilize in more detailed regulation of the
BMP response. Unfortunately, based on this analysis we
were not able to define a specific transcription factor
chromatin signature that could be used to define BMP-
specific regulatory sequences. Hence detailed analysis
of the putative enhancer regions would require more
specific measurement data about the chromatin inter-
actions in these cells.
To further characterize the regulation of BMP4 target
genes, we analyzed transcription factor binding sites
(TFBSs) in the open chromatin regions located on gene
promoters. Among the top 15 enriched TFs, there were a
few which had previously been linked to BMP target gene
regulation. For example, XBP1 and RELA have been
shown to be repressors of BMP target genes Xvent-2 and
Id1, respectively [27, 28]. Using enrichment of the TFBSs
between cell lines as well as other criteria, we selected
three TFs (CBFB, HIF1A, and MBD2) for functional
characterization and silenced them in the two cell lines. In
addition, we used SMAD4, a key component of the ca-
nonical BMP pathway, as our positive control and indeed
SMAD4 was required for transcriptional regulation of all
the BMP4 target genes in the assay. Although BMPs can
signal through alternative pathways [7, 8], this result
points to regulation through the canonical pathway. In
contrast, the response to other transcription factors was
more variable and cell line-specific.
MBD2 is a methyl-CpG-binding transcription factor
that plays a role in development [29, 30]. Several studies
have shown that MBD2 acts as a transcriptional repres-
sor by recruiting co-repressor complexes to promoters,
which in turn leads to formation of repressive chromatin
through chromatin remodelling [31, 32]. However, there
is also evidence that MBD2 can activate transcription by
removing methylation from CpG islands located in pro-
moters [33]. In both cell lines, MBD2 seemed to act
mainly as an activator of transcription, although its role
was more prominent in MDA-MB-231. In our analysis,
MBD2 had a large number of binding sites across DEGs
and it was highly expressed in both cell lines, consistent
with the observed behavior in the silencing experiment.
The key role of MBD2 in controlling the BMP4 response
suggests that DNA methylation may be involved in BMP4
signaling.
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The core-binding factor subunit beta (CBFB) together
with the alpha subunit (RUNX1 or RUNX2) is involved
in hematopoiesis and skeletal development [34, 35]. It
was generally an activator of transcription in T-47D
cells where its binding sites were enriched at DEGs
promoters, but showed a less constant role in MDA-
MB-231. Of note, CBFB has previously been found to
influence BMP signaling in chondrocytes [36] and it
has also been shown to have invasive properties in
breast, prostate and ovarian cancer cells [37, 38].
Hypoxia-inducible factor 1-alpha (HIF1A) is a key
regulator of the hypoxia response and has been linked
to breast cancer progression [39]. In our binding site
enrichment analysis, we observed that HIF1A binding
sites are strongly depleted in MDA-MB-231 DEGs al-
though HIF1A has a very high expression in this cell
line. We also found that HIF1A was almost exclusively
a transcriptional repressor of BMP4 target genes in
MDA-MB-231 cells, whereas in T-47D cells it had ei-
ther no effect or acted as an activator of transcription.
Several hypoxia-related genes were found among DEGs,
four in MDA-MB-231 cells (BDKRB2, PDGFB, ANGPTL-
4 and UCN2) and three in T-47D cells (CBFA2T3, EGLN3
and FLT1). Interestingly, some of these genes have also
been linked to cancer progression, for example HIF1A-
dependent upregulation of PDGFB and ANGPTL-4 pro-
motes metastasis of hypoxic breast cancer cells [40, 41].
As an additional interesting aspect, HIF1A has been
shown to activate BMP4 transcription in pulmonary arter-
ial smooth muscle cells and in murine spleen and ES cells
[42–44]. Together these findings support the view that
HIF1A is indeed a cell type-specific repressor that controls
a particular subset of BMP4-activated target genes.
Conclusions
By combining genome-wide computational analyses
and experimental data with functional validation, we
were able to extend our knowledge about BMP4 signal-
ing in breast cancer. This study demonstrates that the
differential responses to BMP4, reduced proliferation
and induced migration, seen in breast cancer cell lines
in vitro, are reflected in the expression pattern of BMP4
target genes, thus allowing us to uncover regulatory mech-
anisms associated with these phenotypes.
By integration of chromatin state and transcription
factor binding analyses with gene expression, we were able
to identify candidate TFs involved in the regulation of
BMP4 response. The function of these TFs was then tested
by silencing experiments. From our three candidates,
MBD2 emerged as a consistent activator of target gene ex-
pression in both cell lines, while HIF1A was shown to act
as a repressor in cells with induced migration phenotype
and CBFB as an activator, particularly in cells with re-
duced proliferation phenotype.
While understanding the full complexity of the regula-
tion of BMP4 signaling will require more extensive data,
analyses and experiments in wider contexts, our current
study established the existence of phenotype-specific
BMP response patterns in gene expression. Furthermore,
we identified and experimentally validated cell type-
specific downstream regulators of BMP signaling that re-
late to these expression patterns and thus to different in
vitro phenotypes.
Methods
Breast cancer cell lines and treatments
Breast cancer cell lines BT-474, HCC-1954, MCF-7,
MDA-MB-231, MDA-MB-361, MDA-MB-436, and T-
47D as well as the normal immortalized mammary gland
cell line MCF-10A were purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA) and
cultured according to the recommended conditions. The
cell lines were authenticated by genotyping and were regu-
larly tested for mycoplasma infection. Cells were seeded,
allowed to adhere for 24 h, and treated with 100 ng/ml re-
combinant human BMP4 protein (R&D Systems, Minneap-
olis, MN, USA) or vehicle (BMP4 dilution solution). For
RNA-seq and DNase-seq, one sample per cell line and
treatment was used. Samples were collected 3 h after the
treatment, based on our previous results showing SMAD1/
5/9 protein phosphorylation [9] and gene expression
changes by microarray analyses at this time point [14]. For
qRT-PCR, samples representing three biological replicates
were collected at indicated time points and pooled.
RNA purification and sequencing library preparation
Total RNA was extracted from BMP4- and vehicle-
treated cells using the Absolutely RNA miRNA kit
(Agilent Technologies, Palo Alto, CA, USA) according
to the manufacturer’s instructions. RNA quality was
monitored using Agilent 2100 Bioanalyzer (Agilent
Technologies). Sequencing libraries were generated
using the TruSeq RNA Library Prep kit (Illumina Inc.,
San Diego, CA, USA) according to the manufacturer’s
directions. Shortly, total RNA was enriched for Poly-A
tails and then fragmented. Subsequently, RNA fragments
were reverse transcribed into cDNA using random hex-
amer primers. Then, short fragments were purified and
resolved with EB buffer for end reparation and adding
poly(A). After that, the short fragments were ligated to
sequencing adapters. Finally, suitable fragments were se-
lected for the PCR amplification as templates and sepa-
rated with agarose gel electrophoresis before sequencing.
Preparation of DNase I-treated DNA and sequencing library
Cells were grown to 80–90% confluency, treated with
BMP4 or vehicle for 3 h, and 3 × 107 nuclei were iso-
lated as previously described [16]. DNase I digestion
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was performed according to the protocol by Ling and
Waxman [45]. First, 7.5 × 106 nuclei were subjected to
varying amounts of DNase I and different digestion times
in order to optimize the conditions. The qPCR-based
DNase hypersensitive site (DHS) cleavage assay [45] was
performed using positive control primers surrounding
known DHSs in the promoters of housekeeping genes and
negative control primers from intergenic insensitive sites
(Additional file 9: Table S8). Based on these analyses, 40
units of DNase I for 15 min was selected for the DNase I-
treatment. The digestion reaction was followed by phenol-
chloroform extraction and size fractionation of DNase I-
released fragments by sucrose gradient ultracentrifugation.
The DNA fraction with optimal enrichment of DHSs was
chosen based on the qPCR-based fragment release assay
[45]. Positive control primers were located inside known
DHSs in the promoters of housekeeping genes and nega-
tive control primers in gene-free regions of different chro-
mosomes (Additional file 9: Table S8). Fraction 7 gave
optimal results (DNA fragments less than 1 Kb in size) in
all cases and was therefore used for the subsequent steps.
Libraries were generated using BGI’s in-house protocol.
Shortly, 3′-dA overhangs were added and methylated se-
quencing adaptors were ligated to the DNA fragments.
This was followed by PCR amplification and size selection
to 200–400 bp, including the adaptor sequence. Un-
digested DNA from both cell lines was included as an in-
put control.
Deep sequencing
All library construction and deep sequencing steps were
carried out at the Beijing Genomics Institute (BGI)
(Hong Kong) according to their standard practice. Se-
quencing was performed on the Illumina HiSeq2000
platform (Illumina). Raw image files were processed by
Illumina pipeline for basecalling with default parameters.
Reads with too many N bases (>10%) or low base quality
(>50% bases with base quality <5) were discarded. On
average, we obtained 49 million 90 bp-long paired-end
reads from the RNA-seq. For MDA-MB-231 cells,
49,403,872 reads were obtained for the BMP4-treated
sample, while 49,424,070 reads resulted from the vehicle-
treated sample. The equivalent read amounts for T-47D
cells were 49,369,676 and 49,232,294, respectively. Se-
quencing of the DNase I-digested samples yielded on
average 70 million 50 bp-long single-end reads. The
specific read amount for MDA-MB-231 cells treated
with BMP4 was 70,714,004, and 70,339,810 for vehicle-
treated cells. The analogous numbers for T-47D cell
line were 79,353,149 and 65,606,222.
Read alignment and normalization of RNA-seq data
RNA-seq reads were aligned using TopHat2 against hg19
reference genome [46]. On average, we were able to align
96% of the reads. For MDA-MB-231 cells, 96.45% of the
reads were aligned for the BMP4-treated sample, while
96.55% was the analogous value for vehicle-treated sam-
ples. The equivalent numbers for T-47D cell line were
96.33% and 96.02%. Raw expressions were calculated as
simple read counts for composite genes constructed from
the set of transcripts included in Gencode Genes version
19 [47] using the in-house tool Pypette (https://github.
com/annalam/pypette) which is a toolkit built upon
Samtools and Bedtools [48, 49]. Read counts were normal-
ized across samples using median of ratios normalization
implemented similarly as in DESeq2 R-package [50].
Differential gene expression and GO analysis
In order to find differentially expressed genes (DEG) be-
tween BMP4- and vehicle-treated samples, log2 ratios
were calculated. Genes having a log2 ratio absolute value
of 0.75 or greater were considered differentially expressed.
As additional criteria for DEGs, the absolute difference in
read counts between the two treatments was required to
be at least 50. Functional classification of the differentially
expressed protein-coding genes was performed using the
DAVID 6.8 version [51, 52].
Survival analysis of DEGs
Each differentially expressed protein - coding gene was
tested for association with the survival of breast cancer
patients based on the gene expression data obtained
from The Cancer Genome Atlas (TCGA) [53, 54]. The
patients included in the dataset (n = 1212) were divided
into low and high expression groups based on the median
expression of the gene. The difference in the survival
times between the two groups were tested using the log-
rank test and Benjamini-Hochberg correction was applied
to the P-values. The survival analysis was implemented
using the R-package RTCGA toolbox [55].
Read alignment of DNase-seq data and detection of
DNase hypersensitive sites (DHSs)
Reads were aligned using bowtie2 [56]. On average, we
were able to align 97% of the reads. For MDA-MB-231
cells, 97.49% of the reads were aligned for the BMP4-
treated sample, while 97.40% was the analogous value
for vehicle-treated samples. The equivalent numbers for
T-47D cell line were 97.45% and 97.75%. DNase hyper-
sensitive sites (DHSs) were detected using DFilter [57].
The standard deviation was set to 2, bin size 100 bp and
kernel size 50. In addition, the refine parameter was
used. To mitigate the effects of mappability and coverage
bias samples that had not been treated with DNase I
were used as input controls. To remove likely false posi-
tives, all DHSs that were covered by less than 20 reads
in sample or in input control were omitted from further
analysis. Similarly, DHSs located in positions overlapping
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blacklisted regions collected by the ENCODE consor-
tium were filtered out [58]. Additionally, adjacent DHSs
(distance between peaks 100 bp or less) were merged to-
gether. The merged DHSs were annotated by their asso-
ciation to genomic features obtained from Gencode
Genes version 19 using Bedtools [49].
Benchmarking the detected DHSs against available
ENCODE datasets
To confirm the consistency of the results of our DHS
detection in comparison to available ENCODE data, two
DNase-seq datasets, each consisting of two T-47D un-
treated replicates, were retrieved from GEO (accession
numbers: GSM816673 and GSM1024762) [59, 60]. The
alignment of reads and peak detection were done ac-
cording to the workflow described above. Further on, we
refer to these datasets by their ENCODE biosample
identifiers: ENCSR000ELT and ENCSR000EQB.
Finding differential DHSs (ΔDHS) and functional
enrichment analysis
In order to describe the change in chromatin hypersensi-
tivity, DHS change scores (ΔDHS) were calculated be-
tween the two conditions using a slightly modified
formula to the one introduced by He et al. [61]. The




























treated is the number of reads mapped to DHS in
the treated sample and ni
vehicle is the number of reads
mapped to the DHS in the vehicle sample.
The DHSs having ΔDHS equal or greater than 0.20
were selected for enrichment analysis. The analysis was
conducted with GREAT version 3.0.0 [17] using the de-
fault parameters. The results were ranked and selected
based on the binomial test such that all FDR adjusted p-
values were required to be less than 0.05. To filter out
overly generic ontology terms all categories including
more than 1000 genes were filtered out from the final
results of the analysis. In addition, too small categories
including less than ten genes were removed.
Calculation of DNase coverage of TSS and correlation
with gene expression
All possible transcription start sites (TSS), collected from
GENCODE transcripts corresponding to protein - coding
genes, were extended 1000 bases to both directions. The
coverage was calculated for each of these extended TSS
regions, which we further refer to simply as TSS. Further-
more, to obtain a single coverage value to describe the
openness of the TSS for each protein - coding gene, a
weighted sum of the coverages of the TSSs over all the
transcripts associated to that gene was calculated. The
weight for each transcript’s TSS was determined based on
the ratio of the estimated expression of the transcript and
the total expression of the gene, which was calculated
using RSEM [62]. In case the gene was not expressed in
either vehicle or stimulated condition, the same ratio
which was observed in the other condition was used.
Moreover, if the gene was not expressed in either condi-
tion, the maximum TSS coverage over all the transcript’s
TSSs was used as the representative coverage of the TSS
of the gene. For visualization purposes, the chromatin sta-
tus of each gene’s TSS was classified into two categories:
closed or open. A TSS was considered to be closed if its
coverage belonged to the 1. quintile of the TSS coverages
of all genes, in that particular cell line and condition.
Otherwise the TSS was considered to be open. Each TSS
was associated to the corresponding normalized expres-
sion value of the gene, which had been obtained by divid-
ing the expression value obtained after median of ratios
normalization by the gene’s total exon length.
Prediction of transcription factor binding sites in
promoters of upregulated genes
In order to find potential transcriptional regulators of
BMP4 response, DHSs overlapping proximal promoters
(2000 bp upstream regions) of upregulated genes in
MDA-MB-231 and T-47D cell lines were scanned with
Position Weight Matrices (PWMs). Due to the low
signal-to-noise ratio observed in T-47D samples some
DHS regions might be narrower or even absent in the
data as can be concluded by comparing the promoter-
associated DHS regions between our T-47D samples to
untreated ENCODE DNase-seq datasets described earl-
ier (see Additional file 5: Table S5). In order to increase
the robustness of our analysis we created a composite
dataset by taking the union of all promoter-associated
DHSs across our samples and all untreated ENCODE
samples. The PWMs were created from the curated col-
lection of Weighted Position Count Matrices (WPCMs)
retrieved from HOCOMOCO database (version 9) [63].
The PWMs were calculated from weighted matrices of
positional counts (WPCM) using the following formula
previously introduced by Makeev et al. [64]:
Sb;i ¼ ln xb;i þ aqbW þ að Þqb
,where xb,i is the positional count of base b in the i:th
column of WPCM, W is the total weight of the WPCM,
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a is the pseudo count defined as ln(W) and qb is the
background frequency of base b calculated across all the
analyzed sequences.
The score for transcription factor binding match (Mj)
was obtained for each position within the peaks by scan-
ning the sequence using the previously defined PWMs.
The score for position j when scanning with PWM S of





Sb iþjð Þ; i
We considered a PWM to be a match if the PWM
score had a p-value less or equal than 0.001. The score
thresholds corresponding to the used p-value cut-off
were determined using MACRO-APE [65].
Finding enriched and depleted transcription factor
binding sites (TFBS) in promoters of upregulated genes
In order to find enriched transcription factor binding
sites a background model was generated by selecting the
DHSs of all proximal promoters not included in the set
of promoters of upregulated genes as the background
set. The background set was scanned for transcription
factor binding sites as above. Based on the background
set, the expected number of transcription factor sites
were calculated for the promoter sets of upregulated
genes for MDA-MB-231 and T-47D by first dividing the
total number of found TFBSs by the cumulative length
of the scanned DHSs in the background set and then
multiplying this ratio by the cumulative length of the
scanned DHSs in the corresponding promoter set of up-
regulated genes. The ratio of enrichment was then calcu-
lated by dividing the observed TFBSs by the number of
expected TFBSs.
Co-localization enrichment analysis of selected TFs and
known consensus SMAD4-motifs
Six elements including: CAGACA, GTCT, CAGC, CGCC,
GGCGCC and GCCGnCGC which have been previously
reported as Smad-binding elements (SBEs) [66–69] were
selected for co-localization enrichment analysis. The ana-
lysis was conducted such that all TFBSs which fall within
200 bp distance of a consensus motif were considered as
co-localized with the motif. The binomial test was used to
test for enrichment.
qRT-PCR
Quantitative real-time PCR was performed using the
Lightcycler 2.0 instrument (Roche, Mannheim, Germany)
with LightCycler® TaqMan® Master reaction mix (Roche).
Universal probe library (UPL) probes (Roche) and associ-
ated primers (Sigma-Aldrich, St. Luis, MO, USA) were
used for most of the genes, and the LightCycler FastStart
DNA Master SYBR Green I assay (Roche) for the rest.
Roche’s Reference Gene Assay for HPRT was used for
normalization. Primer sequences and probe information
are given in Additional file 9: Table S9.
Transcription factor silencing
Transfections to silence the selected TFs in MDA-MB-
231 and T-47D cells were performed on 24-well plates
using 10 nM siRNA (siGENOME SMARTpool siRNAs,
Dharmacon, Lafayette, CO, USA) and either the Interferin
reagent (Polyplus-Transfection, SanMarcos, CA, USA) or
DharmaFECT (Dharmacon) according to manufacturer’s
instructions. An ON-TARGETplus Non-targeting Control
Pool was used as control (Dharmacon). The knock-down
of TFs was confirmed by qRT-PCR and at least 80%
reduction in mRNA level was considered as adequate
silencing. Forty-eight hours after the transfection, the cells
were treated with 100 ng/ml BMP4 or vehicle for 24 h.
Cell samples were collected by pooling three identically
treated wells and RNA was isolated for subsequent qRT-
PCR analyses.
Additional files
Additional file 1: Figure S1. Relationship between chromatin status of
TSS and gene expression. The boxplots illustrate the distribution of
DNase-seq read coverage at TSS for protein-coding genes at five different
levels of gene expression, which were determined by division of expres-
sions into quintiles. Panel A shows the results obtained from untreated
MDA-MB-231 cells and panel B the corresponding results for untreated T-
47D cells. Panels C and D illustrate the difference between non-expressed
and differentially expressed (protein - coding) genes in terms of the chro-
matin status at TSS in vehicle-treated samples of MDA-MB-231 and T-47D
cells, respectively. In both cell lines, chromatin is clearly open at the TSS
of differentially expressed genes before the stimulation with BMP4.
(PDF 2463 kb)
Additional file 2: Table S1. Differentially expressed genes after BMP4
treatment in MDA-MB-231 cell line. Ensembl IDs, read counts, fold
changes and Log2 ratios are shown. The genes are arranged in order
from the largest to smallest Log2 ratio, first upregulated genes and then
downregulated genes. (XLSX 20 kb)
Additional file 3: Table S2. Differentially expressed genes after BMP4
treatment in T-47D cell line. Ensembl IDs, read counts, fold changes and
Log2 ratios are shown. The genes are arranged in order from the largest
to smallest Log2 ratio, first upregulated genes and then downregulated
genes. (XLSX 34 kb)
Additional file 4: Table S3. Survival analysis of DEGs in MDA-MB-231.
Table S4. Survival analysis of DEGs in T-47D. Each differentially expressed
protein - coding gene was tested for possible association with the sur-
vival of breast cancer patients based on the gene expression data ob-
tained from The Cancer Genome Atlas (TCGA). Blue background indicates
DEGs shared by both cell lines. Benjamini-Hochberg corrected P-values
are shown. No diff. = no association with survival. Not available = not
found in TCGA data. (XLSX 16 kb)
Additional file 5: Table S5. Comparison between our T-47D DNase-seq
data and analogous data from ENCODE. DNase-seq peaks from promoter
regions in BMP4-treated and vehicle-treated T-47D cells were compared
to DNase-seq data of T-47D promoters from ENCODE (ENCSR000ELT
replicates 1 and 2; ENCSR000EQB replicates 1 and 2). The table shows the
percentage of shared peaks between pairs of samples. A high percentage
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of the peaks identified in our data are also present in ENCODE samples
(cells B6-E7). (XLSX 8 kb)
Additional file 6: Figure S2. Shared DNase-seq peaks between BMP4
and vehicle samples. The number of shared peaks and the number of
unique peaks in each treatment group are indicated in the Venn diagram.
(PDF 153 kb)
Additional file 7: Table S6. MDA-MB-231 GREAT analysis. Table S7. T-
47D GREAT analysis. Enrichment of open chromatin peaks using GREAT.
Red color denotes categories that are the same as in the RNA-seq ontol-
ogy analysis. (XLSX 146 kb)
Additional file 8: Figure S3. Transcription factor validation. The chosen
TFs were silenced and then treated with BMP4 before measuring target
gene expression using qRT-PCR. The transcription factor and cell line in
question is stated at the beginning of each page. DLL, which is downregu-
lated in T-47D upon BMP4 treatment, is circled with red. (PDF 256 kb)
Additional file 9: Table S8. Primers used for DNase-seq. Table S9. Primer
sequences for qRT-PCR based expression analyses of BMP4 target genes
and transcription factors. (DOCX 19 kb)
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